The team is comprised of management experts who have extensive technology research and development experience. Their professional experience and corporate vision will lead to the promotion of the anti-IL-20 antibody to the international stage and far ranging health and economic benefits.
- Hung Huei Huang, Chair:
Tom Boone, President:
Dr. Hung, as the head of government agencies for many years, successfully led the NCKU to the top of the universities in academic-industry cooperation in the word. His expertise is in administrative management.
Ming Shi Chang, Chief Scientific Officer:
Tom had served as a scientist doing research and development work for 30 years at Amgen. His expertise is in protein engineering and purification. He was responsible for bringing many molecules to the clinic and the market, including approved drugs such as Neupogen.
Ming-Shi, a director and professor of biochemistry at National Cheng Kung University, previously worked at Amgen, the world’s top biotechnology company, leading the company to identify RANKL as an osteoporosis target and to develop denosumab, a mAb against RANKL, to treat osteoporosis.
Goals and Plan
Since 2014, many of the patents for the best-selling drug patents have faced expiration, the antibody drug market layout has changed to new territories, and monoclonal antibody drug development will lead the global biotechnology industry.
In the field of IL-20 research, whether academic publication, translational medicine research, clinical trials, or patents, our research results are innovative and occupy a leading position in the world.
The advantages of the anti-IL-20 antibody are as follows:
- Most of the USA patents of IL-20 antibody for treating diseases have claims to cover “ANY anti-IL-20 antibodies “.
- Anti-IL-20 antibody is not only a very potent drug to treat several diseases that otherwise do not have effective treatment, but its worldwide patents have been recently granted, so there should be no concerns over patent expiration dates and patent landscape.
In recent years, the compound annual growth rate of monoclonal antibodies has been the highest of all protein drugs. Therapy with monoclonal antibodies is mainly used in autoimmune disease treatment accounting for 46%, followed by cancer treatment at 41%, and 13% for other diseases, including infection, cardiovascular disease, and respiratory diseases. Humanized antibody drugs have the highest market share, accounting for more than 50% of the overall antibody drugs, followed by chimeric antibodies accounted for 28%. In view that the humanized antibody can reduce the body’s immune response to the antibody itself, the future market trend will be for humanized and fully human antibodies.. Following successful human clinical trials of our anti IL-20 antibody, it is certain that significant market share will be captured. Anti-IL-20 antibody that will be used to treat the above three diseases, has an estimated value of USD 140.5 billion per year.